Simon is an experienced CEO and was central to founding MonTa Biosciences in 2015. He has since then led the company through several rounds of financing and secured licensing and patenting of the companys current assets. Simon has together with the MonTa Team developed MBS8 from Bench to Bedside through establishment and scale up of MBS8 production, engaged on the regulatory strategy, conducted IND enabling studies and completing CTA filing for our ongoing clinical study. Simon is an executive manager in the biotech industry and is experienced in innovation, entrepreneurship, management, drug development, regulatory, strategy, oncology, immunology, drug delivery, patenting and licensing. See more about Dr Jensen here.

Morten is the CDO of MonTa Biosciences and is responsible for CMC and development of MBS8 through upscaling and production of MBS8 as well as being heavily involved in clinical development and operations. Prior to joining MonTa Morten has held management positions in the biotech industry and has led several drug development programmes from tox/safety through clinical phases. Morten has a background in managing drug development activities in the biotech industry and is experienced in CMC, clinical trials, regulatory interactions and vendor management. See more about Mr Petersen here.

Steven is an seasoned healthcare and biotech professional with extensive knowledge of research and development, clinical development within oncology as well as medical and regulatory affairs. His background encompasses senior management and hands-on experience from pharmaceutical, biopharmaceutical, biotechnology and diagnostic industries in Europe and the United States. Previous positions include senior assignments at: Novo Nordisk, Dade Behring, Zealand Pharma, BioInvent, Hansa Medical. See more about Mr Glazer here.

Thomas is a serial entrepreneur and has started a number of biotech companies in Denmark and the US. Thomas is currently CEO of a British biotech company and experienced in biomaterial engineering for drug delivery and imaging applications. Thomas has a strong academic experience in the fields of organic chemistry, biophysics, nanotechnology and nanomedicine, drug delivery and cancer biology, and holds a track record of more than 70 research or review articles and patent applications.  

Lone Schøtt Kunøe is CEO of Consolidated Holdings A/S and has a master of science in Economics. She has a background in the Danish central bank and in the predecessor of the European Central Bank before she got into management consulting and recruitment at the consultancy company Mercuri Urval.  She has been with Consolidated Holdings for almost 20 years – first as CFO and later as CEO mostly occupied with M&A as well as being chairman or board member of a number of companies – all part of the Consolidated Holdings’ portfolio of companies.

Dr. Boel has 40 years of experience in international biopharmaceutical R&D, including 22 years as a leader of R&D units at Novo Nordisk, where he was responsible for building and heading a 240+ employee international protein-biotechnology organization. He has served as member of executive teams, as BoD/SAB member and as senior advisor for several high-profile antibody- and immunology-based companies and he has (co)authored 75 original research articles and reviews within several scientific and biomedical disciplines. See more about Dr Boel here.

Sven Madsen is CFO in Consolidated Holdings A/S and has a background as an auditor in a number of auditing firms. Sven Madsen has been working with corporate reporting, financing, and corporate management in Codan Insurance, FLS Industries, SystemForum, Atea and Consolidated Holdings. His special competencies are financial accounting, economic and financial trouble shooting and mergers and acquisitions, and is board members in a number of companies. Sven Madsen also holds a Graduate Diploma in Financial and Management Accounting and an MSc in Business Economics and Auditing. See more about Mr Madsen here.

Soren Tulstrup has more than 30 years of senior level experience within the global life science industry as CEO/Managing Director /Global Franchise Head/Region Head and board director at leading and fast growing companies, most recently CEO of Hansa Biopharma AB and earlier CEO of Swiss specialty pharma company Vifor Pharma and CEO of Danish biotech company Santaris Pharma (now part of Roche). Prior to his CEO roles, Soren Tulstrup spent two decades in senior executive roles in leading pharmaceutical companies, including 12 years at Merck & Co. where he led several subsidiaries in Europe and served as a VP in the global diabetes & obesity franchise at HQ in the US. See more about Søren here